PYRIDOPYRIMIDINE DERIVATIVES AS P2X INHIBITORS Russian patent published in 2025 - IPC C07D471/04 C07D475/02 C07D475/06 C07D487/04 A61K31/519 A61P11/06 A61P11/14 

FIELD: chemistry.

SUBSTANCE: invention relates to compounds selected from (R)-6-(4-fluorophenyl)-N-(1-(6-methylpyridazin-3-yl)ethyl)pyrido[2,3-d]pyrimidin-4-amine, N-((6-methylpyridazin-3-yl)methyl)-6-(5-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-amine, (R)-6-(5-methylpyridin-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)pyrido[2,3-d]pyrimidin-4-amine, (R)-6-(5-chloropyridin-2-yl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)pyrido[2,3-d]pyrimidin-4-amine, (R)-6-(4-fluorophenyl)-N-(1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)pyrido[2,3-d]pyrimidin-4-amine, N-((6-methylpyridin-3-yl)methyl)-6-(p-tolyl)pyrido[2,3-d]pyrimidin-4-amine, N-((6-methylpyridin-3-yl)methyl)-6-(5-methylthiophen-2-yl)pyrido[2,3-d]pyrimidin-4-amine, N-((3,5-difluoropyridin-2-yl)methyl)-6-(4-fluorophenyl)pyrido[2,3-d]pyrimidine-4-amine, 6-(4-fluorophenyl)-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]pyrido[3,4-d]pyrimidin-4-amine, and so forth, which have an inhibitory effect on purinergic receptor 3 (P2X₃). Invention also relates to a pharmaceutical composition containing said compounds.

EFFECT: compounds can find application in treating a disease in which P2X₃ receptors are involved.

11 cl, 10 tbl, 107 ex